16951
This open - label , 2 - part , phase I / Ib study ( NCT00800436 ) was undertaken in healthy male volunteers and female patients with HER2 - positive early breast cancer to identify the dose of subcutaneous trastuzumab that resulted in exposure comparable with the approved intravenous trastuzumab dose .
 None
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 None